Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
MitoKor
San Diego, California, United Statesmitokor.com ↗
- Ownership
- Private
- Employees
- ~25
- Development stage
- Other
01
Overview
MitoKor developed multiple preclinical and clinical candidates addressing mitochondrial dysfunction in neurological and degenerative diseases. As of the 2004 Micrologix acquisition, there were two candidates entering Phase III, three in Phase I/II, and seven preclinical programs including in Alzheimer's, arthritis, and Parkinson's disease. All original development as MitoKor has been discontinued under the acquiring company[1][3][4].
- Therapeutic areas
- Metabolic DisordersOncologyNeurology
- Modalities
- Small moleculeBiologic
- Industry
- Biotech
02
Partnerships
PfizerWyeth
Beyond the preview
Go deeper on MitoKor.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MitoKor.